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SUMMARY 
Early full-term pregnancy is one of the most effective natural protections against breast 
cancer; yet the underlying mechanism is poorly understood. To investigate this, we 
characterized the global gene expression and epigenetic profiles of multiple cell types 
from normal breast tissue of nulliparous and parous women. We found that the most 
significant differences are in cells with progenitor features where the levels of many stem 
cell-related genes and pathways including p27Kip1 and TGF are lower in parous women 
except in BRCA1 and BRCA2 mutation carriers. The numbers of p27+ cells are also 
significantly decreased in control parous women, the majority of these cells are estrogen 
receptor (ER+) and phospho-Smad2 (pSmad2+) positive, and their numbers inversely 
correlate with ovarian hormone-induced proliferation during the menstrual cycle and 
pregnancy. Inhibition of TGF signaling in tissue explant cultures decreased the 
numbers of p27+ cells with a concomitant increase in cell proliferation. Our results imply 
that p27+ mammary epithelial cells are hormone-responsive progenitors, their numbers 
correlate with breast cancer risk, and targeting of pathways that control their numbers 
and proliferation can be explored for cancer prevention.  
 
HIGHLIGHTS 
 Parity-related molecular alterations in control but not BRCA1/2 normal breast 
 Stem cell-related pathways are decreased in progenitors from parous tissues 
 Number of hormone-responsive p27+ progenitors correlate with cancer risk 
 p27 and TGF signaling are key regulators of breast epithelial progenitors  
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INTRODUCTION 
A single full-term pregnancy in early adulthood decreases the risk of estrogen receptor positive 
(ER+) postmenopausal breast cancer, the most common form of the disease (Colditz et al., 
2004). Age at first pregnancy is critical, as the protective effect decreases after the mid 20s, and 
women aged >35 at first birth have increased risk of both ER+ and ER- breast cancer. Parity-
associated risk is also influenced by germline variants as BRCA1 and BRCA2 mutation carriers 
do not experience the same decrease in risk reduction as do women in the general population 
(Cullinane et al., 2005). These human epidemiological data suggest that pregnancy induces 
long-lasting effects in the normal breast epithelium and that ER+ and ER- tumors might have a 
different cell-of-origin. 
 The protective effect of pregnancy is also observed in animal models, where it can be 
mimicked by hormonal factors in the absence of gestation (Ginger and Rosen, 2003; Russo et 
al., 2005; Sivaraman and Medina, 2002). The cellular and molecular mechanisms that underlie 
pregnancy and hormone-induced refractoriness to carcinogens are largely undefined. Several 
hypotheses have been proposed including the induction of differentiation, decreased 
susceptibility to carcinogens, a decrease in cell proliferation and in the number of mammary 
epithelial stem cells, an altered systemic environment due to a decrease in circulating growth 
hormone and other endocrine factors, and permanent molecular changes leading to alterations 
in cell fate (Ginger and Rosen, 2003; Russo et al., 2005; Sivaraman and Medina, 2002). 
 Almost all studies investigating pregnancy-induced changes and the breast cancer-
preventative effects of pregnancy have been conducted in rodent models and most of them 
have focused only on the mammary gland. Global gene expression profiling of mammary glands 
from virgin and parous rats identified changes in TGF and IGF signaling, and in the expression 
of extracellular matrix proteins (Blakely et al., 2006; D'Cruz et al., 2002). Related studies 
conducted in humans also identified consistent differences in gene expression profiles between 
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nulliparous and parous women (Asztalos et al., 2010; Belitskaya-Levy et al., 2011; Russo et al., 
2008; Russo et al., 2011). Because all these studies have used total mammary gland or 
mammary organoids, which are composed of multiple cell types, the cellular origin of these gene 
expression differences remains unknown. 
 Emerging data indicate that mammary epithelial progenitor or stem cells are the cell-of-
origin of breast carcinomas and factors that influence breast cancer risk may alter the number 
and/or properties of these cells (Visvader, 2011). Studies assessing changes in mammary 
epithelial stem cells following pregnancy have been conducted only in mice and thus far have 
been inconclusive (Asselin-Labat et al., 2010; Britt et al., 2009; Siwko et al., 2008). Thus, the 
effect of pregnancy on the number and functional properties of murine mammary epithelial 
progenitors is still elusive and it has not yet been analyzed in humans. 
 Here we describe the detailed molecular characterization of luminal and myoepithelial 
cells, lineage-negative (lin-) cells with progenitor features, and stromal fibroblasts from 
nulliparous and parous women, the identification of cell-type-specific differences related to 
parity, functional validation of selected parity-related pathways, and the relevance of these to 
breast cancer risk and survival.  
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RESULTS   
Parity-related differences in gene expression patterns in multiple cell types 
To investigate parity-associated differences in the normal human breast, first we defined three 
distinct mammary epithelial cell populations by FACS (fluorescence-activated cell sorting) for 
cell surface markers previously associated with luminal epithelial (CD24), myoepithelial (CD10), 
and progenitor features (lin-/CD44+) (Bloushtain-Qimron et al., 2008; Mani et al., 2008; Shipitsin 
et al., 2007)  that showed minimal overlap both in nulliparous and parous tissues (Figure S1A-
B). The relative fraction of CD44+ cells was slightly higher in parous relative to nulliparous 
samples, which is likely due to the more developed lobular structures composed of many CD44+ 
cells in these tissues that we observed in sections (Figure S1B-C).  We also performed 
multicolor immunofluorescence analyses for these cell surface markers and genes specific for 
luminal (e.g., GATA3) and myoepithelial (e.g., SMA) cells, to further confirm the identity of the 
cells (Figure S1D). 
 To investigate parity-related differences in global gene expression profiles, we analyzed 
immuno-magnetic bead purified (Bloushtain-Qimron et al., 2008; Shipitsin et al., 2007) CD24+, 
CD10+, and CD44+ cells (captured sequentially, thus, CD44+ fraction is CD24-CD10-CD44+), and 
fibroblast-enriched stroma from multiple nulliparous and parous women using SAGE-seq (Serial 
Analysis of Gene Expression applied to high-throughput sequencing) (Maruyama et al., 2011; 
Maruyama et al., 2010; Wu et al., 2010). To minimize interpersonal variability unrelated to parity 
status, women were closely matched for age, the number of pregnancies, time at first and since 
last pregnancy, and ethnicity (Table S1). The expression of known cell type-specific genes (e.g., 
KRT8 and MUC1 luminal, ACTG2 and CNN1 myoepithelial, ZEB2 and TWIST1 progenitor cell 
markers) was consistently observed in each of the three respective epithelial cell types both 
from nulliparous and parous samples based on SAGE-seq confirming the purity and identity of 
the cells (Figure S1E). Comparison of each cell type between nulliparous and parous samples 
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revealed the most pronounced differences in CD44+ cells, where the number of significantly 
(p<0.05) differentially expressed genes and the fold differences were the largest between 
groups (Figure 1A and Table S2). The degrees of differences were smaller and similar in CD10+ 
and CD24+ cells, whereas stromal fibroblasts had the fewest differentially expressed genes 
(Tables S2). Further examination of parity-related differences in expression patterns using 
principal component analysis (PCA) confirmed that CD24+ and CD10+ cells and fibroblasts from 
nulliparous and parous women were highly similar, whereas CD44+ cells formed very distinct 
nulliparous and parous clusters (Figure 1B and Figure S1F).  
 To validate our parity-related gene expression differences in an independent cohort, we 
analyzed the levels of our differentially expressed genes (in all cell types or only in CD44+ cells) 
in gene expression data from breast biopsies of a cohort of Norwegian women (Haakensen et 
al., 2011a; Haakensen et al., 2011b) matched to our samples for age (<40) and parity (P2). 
Clustering analysis using our differentially expressed gene sets divided these samples into a 
distinct nulliparous and a mixed parous/nulliparous group (Figure SGF). Using genes 
differentially expressed in all four cell types (i.e., CD24+, CD10+, CD44+ cells, and fibroblasts) 
combined or only in CD44+ cells gave identical results, supporting our hypothesis that changes 
in CD44+ cells are the most significant and physiologically relevant. Interestingly, the two 
nulliparous groups displayed significant differences in serum estradiol levels (SEL) with the 
group more similar to parous cases having low SEL; all parous samples also had low SEL 
(Figure S1H). Because these were all premenopausal women and SEL is known to be higher in 
the luteal phase of the menstrual cycle, when breast epithelial cell proliferation is also higher, 
our findings imply that breast tissues of nulliparous and parous women may be more distinct in 
the luteal phase potentially due to differences in the activity of signaling pathways driving cell 
proliferation or the number of cells that respond to these stimuli.  
 The expression of selected genes was also validated in additional samples by quantitative 
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RT-PCR (qRT-PCR) using CD44+ cells from multiple nulliparous and parous cases. Despite 
some interpersonal variability, we detected statistically significant differences between 
nulliparous and parous groups that overall correlated with SAGE-seq data (Figure S1I). 
 Based on these findings in gene expression profiles, we focused our follow up studies on 
CD44+ and CD24+ cells. 
 
Lack of parity-associated differences in BRCA1 and BRCA2 mutation carriers 
To strengthen our hypothesis that the parity-associated differences we detected in CD44+ cells 
might be related to subsequent breast cancer risk, we analyzed the gene expression profiles of 
CD44+ cells from parous BRCA1 and BRCA2 mutation carriers, whose risk is not decreased by 
parity (Cullinane et al., 2005). CD44+ cells from parous BRCA1/2 mutation carriers were highly 
related to CD44+ cells from nulliparous controls (Figure 1C), suggesting that parity-associated 
changes observed in control parous women may not occur in these high risk women.  
 To determine if the lack of parity-associated changes in CD44+ cells from BRCA1/2 
women could be due to differences in the cell populations identified by the three cell surface 
markers, we performed FACS analysis of multiple tissue samples from control and BRCA1/2 
women. The relative ratio of CD44+ to CD24+ cells was slightly higher in control and BRCA1/2 
parous compared to nulliparous control samples, whereas the relative frequency of CD10+ cells 
was about the same in all groups (Figure 1D). The increase in the relative frequency of CD44+ 
to CD24+ cells in parous samples could potentially be due to the increased number of lobulo-
alveolar relative to ductal structures observed in parous women (Russo et al., 2001) or may 
reflect the presence of parity-induced stem cells described in murine mammary glands (Matulka 
et al., 2007; Wagner et al., 2002).  
  
Biological pathways and networks affected by parity-related gene expression changes 
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Because the ultimate goal of our study is to identify targets for chemoprevention that would 
mimic the cancer-protective effects of parity, we investigated which signaling pathways might be 
affected by parity-related molecular changes. As early pregnancy specifically decreases the risk 
of ER+ breast tumors, we first explored our differentially expressed gene lists in CD44+ cells for 
candidate mediators of this effect. We found several genes that may change the response of 
breast tissue to steroid hormones by altering metabolism (e.g., HSD17B11, HSD17B12, and 
HSD17B14) or by modulating nuclear receptors (e.g., NCOR1, NCOR2, NCOA4, and NCOA7) 
(Tables S2). Interestingly, androgen receptor (AR) and one of its key targets PSA (KLK3) were 
highly expressed in nulliparous CD44+ cells, implying active androgen signaling pathway that is 
decreased following pregnancy. Among genes highly expressed in CD44+ parous cells were a 
number of known tumor suppressors, such as Hakai/CBLL1 (Gong et al., 2010), CASP8 (Cox et 
al., 2007), SCRIB and LLGL2 (Humbert et al., 2008), and DNA repair-related genes (e.g., 
PRKDC, FANCB) suggesting that these cells may be more resistant to transformation in parous 
women. 
 In order to determine overall activation of specific biological functions due to parity in the 
cell types analyzed, we performed pathway enrichment, network, and protein interactome 
analyses using the MetaCore platform (Bessarabova et al., 2011; Ekins et al., 2006; Nikolsky et 
al., 2009). We found that parity has similar global effects on three of the four cell types 
analyzed, as pathways built on expression patterns in CD10+ and CD44+ cells and stroma 
cluster together for parous and nulliparous states (Figure 1E). The most significant pathways 
highly active in parous samples in all of these three cell types included apoptosis, survival, and 
immune response, whereas stem cells and development-related pathways were enriched only in 
CD44+ nulliparous cells (Figure 1F and Table S3). Pathways highly active in parous stroma 
were enriched in energy metabolism, fatty acid metabolism and adipocyte differentiation from 
stem cells, which is consistent with adipose tissue development and a decrease in breast 
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density following pregnancy (Boyd et al., 2009). The functional categories of genes affected by 
parity were similar in all four cell types with receptors and enzymes representing the most 
enriched groups (Figure S2A and Table S4). 
 We focused our further analysis on CD44+ cells that showed the most pronounced 
differences between parous and nulliparous states. Pathways highly active in nulliparous 
samples are related to major developmental and tumorigenic pathways including cytoskeleton 
remodeling, chemokines and cell adhesion, and WNT signaling, whereas pathways more active 
in parous samples include PI3K/AKT signaling and apoptosis (Table S3). Importantly, the 
highest scored pathway for genes highly expressed in nulliparous samples is four orders of 
magnitude more statistically significant than those for the genes highly expressed in parous 
samples, suggesting that downregulation of protumorigenic developmental pathways is a 
prominent feature of CD44+ parous cells. Interactome analysis also demonstrated a much larger 
number of overconnected proteins in nulliparous than in parous state in all four cell types, but 
particularly in CD44+ cells (Figure S2A). As the relative number of interactions (connectivity) is 
directly related to the functional activity of the dataset (Nikolsky et al., 2008), this result suggests 
that parous cells are overall substantially less active than nulliparous ones.  
 Because pregnancy-induced protection against breast cancer is also observed in rodents, 
we investigated if pathways altered by parity are conserved across species. We compared 
pathways in CD44+ cells to that generated based on genes differentially expressed between 
virgin and parous rats (Blakely et al., 2006; D'Cruz et al., 2002). We found significant overlap 
between pathways highly active in nulliparous and virgin samples with top ranked pathways, 
including cytoskeleton remodeling and cell adhesion, highly relevant in stem cells (Figure S2B-
C). Thus, pregnancy appears to induce similar alterations in the mammary epithelium regardless 
of species. 
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Cell type-specific epigenetic patterns related to parity and their functional relevance 
Reduction of breast cancer risk in postmenopausal women conferred by full-term pregnancy in 
early adulthood implies the induction of long-lasting changes such as alterations in cell type-
specific epigenetic patterns. To investigate this hypothesis we analyzed the comprehensive 
DNA methylation and histone H3 lysine 27 trimethylation (K27) profiles of CD24+ and CD44+ 
cells from nulliparous and parous women using MSDK-seq (Methylation-Specific Digital 
Karyotyping (Hu et al., 2005) applied to high-throughput sequencing) and ChIP-seq (Chromatin 
Immunoprecipitation applied to high-throughput sequencing) (Maruyama et al., 2011), 
respectively. Comparison of MSDK-seq libraries of nulliparous and parous samples within each 
cell type showed a higher number of significantly (p<0.05) differentially methylated regions 
(DMRs) in CD44+ cells and in both cell types more DMRs were hypermethylated in nulliparous 
than in parous cells (Figure 2A and Table S5).  The differences in DNA methylation of selected 
genes were validated in additional samples by quantitative methylation-specific PCR (qMSP) 
using CD44+ cells from multiple nulliparous and parous cases. Despite some interpersonal 
variability, we detected statistically significant differences between nulliparous and parous 
groups that overall correlated with MSDK-seq data (Figure S2D).  
 To investigate pathways affected by parity-related epigenetic alterations, we analyzed 
pathways enriched by genes associated with gene body or promoter DMRs in CD44+ cells from 
nulliparous and parous samples and found very little overlap among the four distinct categories 
(Figure 2B). The fraction of transcription factors (TFs) among differentially methylated genes is 
2-3 fold higher than expected and what was observed among differentially expressed genes, 
implying that promoter methylation might be a preferred control mechanism of their expression 
(Figure 2C-D). Similar to the expression data, DMRs in nulliparous samples had higher numbers 
of overconnected objects than in parous ones. Gene body DMRs in CD44+ nulliparous cells had 
the highest number of overconnected objects and transcription factors represented a significant 
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fraction of overconnected objects in promoter hypermethylated DMRs in CD44+ nulliparous cells 
(Figure 2D).  
 We also analyzed associations between differential gene expression and presence of 
DMRs in CD44+ and CD24+cells, but did not find any significant correlation at the global scale 
(data not shown) potentially due to the complex relationship between DNA methylation and 
transcript levels as DNA methylation can both positively (e.g., in gene body) and negatively 
(e.g., in promoters) regulate gene expression, depending on the location relative to transcription 
start site (Jones, 1999; Maruyama et al., 2011; Zhang et al., 2006). However, the expression of 
several transcription factors with key roles in stem cells (e.g., HES7, STAT1) was correlated 
with the degree of promoter or gene body DNA methylation (Figure 2E). These findings are in 
agreement with recent data in multiple tissue types where most differentially expressed genes 
did not show significant differences in DNA methylation with the exception of transcription 
factors (Bock et al., 2012).  
 Analysis of the H3K27me3 profiles of CD44+ or CD24+ cells from nulliparous and parous 
samples did not detect significant parity-related differences in either cell types, although cell 
type-specific differences were clearly present (Figure S2E and data not shown). However, 
genes highly expressed in CD44+ or CD24+ cells from nulliparous women were not K27-
enriched in either parous or nulliparous cases implying the potential lack of their regulation by 
the PRC2 complex that establishes this histone mark (Table S6). 
 Overall it appears that pregnancy may have a more pronounced long-term effect on DNA 
methylation than on K27 patterns and that parity-associated differences in DNA methylation only 
affect the expression of a limited number of transcription factors with key roles in development 
and differentiation. 
   
Persistent parity-related decrease in p27+ breast epithelial cells 
    
 12
CDKN1B encoding for p27, was one of the most significantly differentially expressed genes in 
CD44+ cells from nulliparous and parous and also from control and BRCA1/2 parous tissues 
(Table S2). p27 has been reported to affect the number and proliferation of stem cells and 
progenitors in several organs in mice (Cheng et al., 2000; Muraoka et al., 2001; Oesterle et al., 
2011). Thus, the higher expression of p27 in CD44+ cells from nulliparous and BRCA1/2 women 
may indicate higher numbers of mammary epithelial progenitors in these samples. To 
investigate this hypothesis, we performed immunofluorescence analysis for p27 alone and in 
combination with CD24 and CD44 cell surface and Ki67 proliferation markers. We analyzed both 
premenopausal and postmenopausal tissues to confirm that the parity-related differences we 
detected by global profiling of premenopausal women are maintained after menopause. Using 
this approach we observed that the expression level of p27 and the number of p27+ cells was 
significantly lower in parous compared to nulliparous samples from both pre- and 
postmenopausal women (Figure 3A-B). The frequency of Ki67+ cells displayed similar 
differences between nulliparous and parous cases and Ki67+ cells were only rarely p27+ (Figure 
3B-C).  
 To strengthen the link between the frequency of p27+ cells and parity-related decrease in 
postmenopausal ER+ breast cancer risk, we also analyzed postmenopausal nulliparous and 
parous women with or without breast cancer. Although cancer-free nulliparous postmenopausal 
women had higher fraction of p27+ cells than parous ones, the frequency of these cells was the 
highest in parous postmenopausal women with breast cancer (Figure S3A).  
 These data support our hypothesis that p27 may mark quiescent mammary epithelial 
progenitors with proliferative potential and that the numbers of these cells correlate with the risk 
of breast cancer, especially in postmenopausal parous women.  
 
Link between parity-related differences and mammographic density 
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Mammographic density is one of the most significant risk factors for breast cancer and it is 
higher in nulliparous compared to parous women (Boyd et al., 2009). Thus, parity-related 
differences that are the most relevant to breast cancer risk may also correlate with differences in 
mammographic density. To test this hypothesis, we analyzed the expression of p27 and Ki67 in 
biopsy samples obtained from high and low density areas of the same breast (Lin et al., 2011). 
The overall expression of p27 and Ki67 were not significantly different between low and high-
density areas, but the number of p27+ cells was higher in high-density areas (Figure 3D). Thus, 
the numbers of p27+ cells might correlate with both parity and mammographic density-related 
breast cancer risk.  
 
p27+ breast epithelial cells are quiescent hormone-responsive progenitors 
The mutually exclusive expression of Ki67 and p27 in breast epithelial cells with their 
concomitant decrease in parous compared to nulliparous women implied that they may 
represent proliferating and quiescent progenitors, respectively. Ovarian hormones are the best-
understood regulators of breast epithelial cell proliferation and also breast cancer risk (Brisken 
and O'Malley, 2010). Correlating with this, our gene expression data indicated a decrease in AR 
and AR targets in CD44+ cells from parous women (Table S2) and prior studies implied a 
decrease in ER+ breast epithelial cells in parous compared to nulliparous women (Taylor et al., 
2009). 
 To explore the potential hormonal regulation of p27+ breast epithelial cells, we analyzed 
the expression of p27, ER, and AR, in breast tissue samples from women varying parity and 
hormonal status. These included control nulliparous and parous women, parous BRCA1/2 
mutation carriers, breast biopsy tissues from women in early (8-10 weeks) and late (22-26 
weeks) stage of pregnancy, in follicular and luteal phase of the menstrual cycle or undergoing 
ovarian hyperstimulation prior to oocyte collection for in vitro fertilization. Interestingly, we found 
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that nearly all p27+ cells were also ER+ and their numbers were the highest in parous BRCA1/2 
mutation carriers and the lowest in biopsy samples from pregnant women and after ovarian 
hyperstimulation, where both ovarian hormone and hCG (human choriogonadotropin) levels are 
the highest (Figure 4A). The frequencies of p27+, ER+, and p27+ER+ cells were also higher in 
control nulliparous compared to parous women and in follicular relative to luteal phase of the 
menstrual cycle (Figure 4A). Similar observations were made for AR, although the overlap 
between p27 and AR was less pronounced compared to that between p27 and ER (Figure 5B).  
 To further investigate the relationship between the numbers of p27+ cells and ovarian 
hormone-induced breast epithelial cell proliferation, we performed immunofluorescence analysis 
for p27 and Ki67 in tissue samples with the highest differences in hormone levels. Correlating 
with prior data (Chung et al., 2011; Going et al., 1988; Meyer, 1977), the frequency of Ki67+ 
cells was the highest in luteal phase of the menstrual cycle when both estrogen and 
progesterone levels are high (Figure 4C). Samples from early pregnancy had a lower fraction of 
proliferating Ki67+ cells and the numbers of these cells was the lowest in follicular phase. The 
frequency of p27+ cells displayed inverse correlation with that of Ki67+ cells: it was the highest in 
follicular phase and lowest in biopsies from oocyte donors (Figure 4C). Interestingly, a low but 
detectable fraction of p27+ cells was also Ki67+ in luteal phase and early pregnancy, potentially 
marking proliferating progenitors in early G1 phase of the cell cycle. The differences in the 
frequency of p27+ and Ki67+ cells between follicular and luteal phase was less significant in 
parous compared to nulliparous women in part due to the lower overall fractions of these cells in 
parous cases (Figure S3A).  
 These results suggest that a subset of p27+ cells may represent quiescent hormone-
responsive luminal progenitors and that the numbers of these cells correlate with the risk of 
breast cancer. 
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Functional validation of parity-related differences in signaling pathways 
Several signaling pathways less active in CD44+ cells from parous women were related to stem 
cell maintenance and cell proliferation (Figure 1F). To investigate if inhibition of these pathways 
affect the number of p27+ and proliferating cells, we incubated normal breast tissues in a tissue 
explant culture model with inhibitors or agonists of selected pathways (e.g., cAMP, EGFR, 
Cox2, Hh, TGF, Wnt, and IGFR) for 8-10 days after which we assessed the number of p27+ 
cells and cellular proliferation based on bromodeoxyuridine (BrdU) incorporation and Ki67 
expression. 
 Tissue architecture and cellular viability were maintained and p27+, Ki67+, and BrdU+ cells 
were detected in all conditions (Figure 5A,B). The frequency of p27+ cells most pronouncedly 
decreased following TGFBR and IGFR inhibitor treatment (Figure 5C). Treatment with TGFBR 
inhibitor significantly (p<0.05) increased mammary epithelial cell proliferation and the number of 
BrdU+ cells, whereas inhibition of cAMP, EGFR, Cox2, Hh, and IGFR signaling had the opposite 
effects. Inhibition of EGFR and Cox2, and to a lesser degree Wnt and IGFR, decreased the 
fraction of Ki67+ cells, while stimulation with Shh ligand increased it (Figure S3B).  
 To demonstrate that the numbers of and proliferation of p27+ cells is regulated by ER and 
estrogen signaling, we analyzed the fraction of p27+ and Ki67+ cells in tissue slices treated with 
varying concentrations of ovarian hormones or tamoxifen. To be able to correlate the tissue 
slices data with that we observed in physiologic conditions (Figure 4), we used estrogen, 
progesterone, and prolactin hormone levels that mimic serum levels in follicular and luteal phase 
of the menstrual cycle or mid-pregnancy. The numbers of p27+ cells was high in sections treated 
with concentrations of estrogen present in follicular phase and also following tamoxifen 
treatment, whereas it decreased in cultures incubated with luteal phase and pregnancy level 
hormones (Figure 5D and Figure SB). These data further support our hypothesis that a subset 
of p27+ cells are hormone-responsive progenitors.  
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 To establish a direct link between p27+ cells and the signaling pathways analyzed, we 
confirmed that the selected pathways were active in p27+ cells (Figure 6A) and that the 
compounds effectively inhibited their activity in these cells (Figure 6B-C). Most importantly, the 
expression of phosphoSmad2 (pSmad2), a key mediator of TGF signaling, demonstrated a 
nearly complete overlap with p27 both in tissue slices (Figure 6A) and in uncultured tissue 
samples  (Figure 6D). The frequency of p27+pSmad2+ cells also fluctuated according to 
hormone levels displaying inverse correlation in mammary epithelial cell proliferation during 
menstrual cycle and pregnancy (Figures 6D and 4A) These results imply a key role for TGF 
signaling in maintaining mammary epithelial progenitors in a quiescent state via modulating the 
expression of p27 (Polyak et al., 1994).  
 Thus, these data suggest that the decreased frequency of p27+ and Ki67+ cells in parous 
women is a reflection of the decreased activity of stem cell-related signaling pathways after 
pregnancy identifying these pathways as potential targets for cancer preventive interventions. 
 
Parity-associated decrease in mammary epithelial progenitors and breast tumor initiation 
Our data support the hypothesis that a decrease in the number and proliferative potential of 
luminal progenitors in parous women directly relate to a decrease in breast cancer risk and that 
this effect is dependent on the age at first full-term pregnancy. As this hypothesis cannot be 
addressed experimentally in humans, we designed a mathematical model of the dynamics of 
proliferating mammary epithelial cells that can accumulate the changes leading to cancer 
initiation (Figure S4). We considered two types of cells: a self-renewing population of stem cells 
and a population of proliferating hormone-responsive luminal progenitors that result from the 
differentiation of these stem cells. We initiated our simulations at menarche and continued it 
until breast cancer initiation or death. We tested the effect of pregnancy on breast cancer 
initiation at varying times after menarche and compared these results with the risk of tumor 
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initiation in nulliparous women. We tested the robustness of our simulation over varying 
numbers of stem cells per terminal end duct, additional proliferative capacities resulting from 
pregnancy, and rates of asymmetric stem cell division. We then compared the relative likelihood 
of cancer initiation with pregnancy occurring at four different time points during childbearing 
years as compared to nulliparous simulations (see Supplementary Information for details). We 
found that the probability of cancer initiation in a duct increases as the age at first pregnancy 
increases (Figure 7A and S5). Furthermore, our simulations imply that differences in the 
numbers of luminal epithelial progenitors with proliferative potential are the most probable 
explanation of differences in breast cancer risk due to reproductive (e.g., parity) and genetic 
(e.g., BRCA1/2 germline mutation) factors.  
 
Prognostic relevance of parity in breast cancer patients 
Our gene expression and immunofluorescence data suggest that the numbers and properties of 
luminal progenitors are different in nulliparous and parous women. If these cells participate in 
breast cancer initiation then tumors developing in parous and nulliparous women might also be 
different and this might impact their gene expression profiles and clinical outcome. To test these 
hypotheses, we first investigated the effect of parity on breast cancer-specific survival in the 
Nurses’ Health Study (NHS), a cohort including 121,700 women followed since 1976 (Colditz et 
al., 1995). Overall, Kaplan Meier curves show that there is no significant association between 
parity and breast cancer-specific survival (p=0.29). However, when the analysis was limited to 
ER+ tumors, we found that nulliparous women had a suggestive worse survival compared with 
parous women (Figure 7B). In multivariate analysis there was still a marginally significant 
association among women with ER+ tumors, with nulliparous women having a nearly 30% 
increased risk of death from their disease (HR: 1.29, 95% CI: 0.98, 1.70; p=0.06). Assessing 
associations between age at first pregnancy and number of pregnancies gave similar results 
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(data not shown). In contrast, among women with ER- tumors, parity was not associated with 
breast cancer-specific survival (P=0.51). Thus, parity may also influence the clinical outcome of 
breast cancer patients with ER+ tumors.  
Because pregnancy may not induce the same epigenetic and gene expression changes 
in all women due to germline variations, we next investigated if our parity-related gene 
expression signature (PAGES) in CD44+ cells might be a more useful prognostic marker than 
parity status alone. Thus, we analyzed the expression of PAGES in public breast cancer gene 
expression data with clinical outcome. We applied the supervised principle component analysis 
(SPCA) on one of the cohorts (Wang et al., 2005) as a training set to identify the subset of the 
PAGES with prognostic value followed by validation in three other cohorts (Desmedt et al., 
2007; Sotiriou et al., 2006; van de Vijver et al., 2002) (Figure 7B and Figure S4A-C). In each 
dataset we selected ER+ tumors, the tumor subtype affected by parity, and cases without 
systemic therapy in order to avoid differences due to treatment. All patients in the training set 
had small (<2cm), lymph node negative tumors at the time of diagnosis. Using this approach, 
we identified parity-related gene signatures that split patients into two distinct groups with 
significant survival difference (Table S7). Interestingly, such prognostic signature was found 
among genes highly expressed in both nulliparous and parous samples and each set of genes 
could be further separated into good and bad signatures (Figure 7B and Figure S4A-C). These 
results reflect the complex relationship between pregnancy and breast cancer that involves both 
protective and tumor-promoting effects (Schedin, 2006).  
 
DISCUSSION 
Our comprehensive analysis of multiple cell types in normal human breast tissue from 
nulliparous and parous women implies that parity has the most pronounced effect on luminal 
progenitors enriched in CD44+ cell fraction. Most of the differences relate to transcriptional 
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repression and downregulation of genes and pathways important for stem cell function including 
EGF, IGF, Hh, and TGF signaling. Correlating with our findings, high circulating IGF-1 levels 
have been associated with increased risk of ER+ breast cancer (Key et al., 2010). Similarly, 
germline polymorphism in members of the TGF signaling pathway influence breast cancer 
susceptibility (Scollen et al., 2011).       
 One of the intriguing findings of our study is the high numbers of p27+ cells in breast 
tissues of nulliparous women and parous BRCA1/2 mutation carriers with high risk of breast 
cancer, which seems paradoxical as CDKN1B/p27kip1 is a bona fide tumor suppressor and 
potent inhibitor of cell cycle progression. However, p27 has been shown to play an important 
role in stem and progenitor cells, best characterized in the murine hematopoietic and nervous 
system, where loss of p27 increases the number of transit amplifying progenitors but not that of 
stem cells (Cheng et al., 2000; Mitsuhashi et al., 2001; Oesterle et al., 2011). In the mouse 
mammary gland, the consequences of p27 deficiency have been controversial. The role of p27 
in mouse breast epithelium has been assessed based on mammary transplant assays (Muraoka 
et al., 2001) due to infertility and hormonal defects of female p27/Cdkn1b -/- mice (Fero et al., 
1996; Kiyokawa et al., 1996). Using this approach, in one study p27 deficiency was associated 
with hypoplasia and impaired ductal branching and lobulo-alveolar differentiation (Muraoka et 
al., 2001), a phenotype consistent with a putative role for p27 in regulating the number and 
proliferation of breast epithelial progenitors (although this was not investigated). In contrast, 
another study using the same strain of mice found increased cell proliferation but no defects in 
ducto-alveolar branching and differentiation (Davison et al., 2003).  
 Similarly, the effect of p27 deletion on mammary tumorigenesis has been analyzed by 
crossing MMTV-neu and p27+/+, +/-, and -/- mice (Muraoka et al., 2002). The number of neu-
induced tumors increased in p27 +/- background compared to p27 +/+, whereas the number of 
tumors in MMTV-neu/p27-/- mice was decreased. The authors attributed these findings to the 
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cell autonomous effects of p27 on cyclin D-cdk4 complex formation and activity, and the 
potential role of p27 in the regulation of the numbers of tumor initiating cells was not 
investigated. Nevertheless, these data are consistent with our hypothesis that p27 plays a key 
role in mammary epithelial progenitors. Correlating with this, our analysis of stem, luminal 
progenitor and mature luminal cells from mammary glands of virgin and retired breeder (i.e., 
parous) mice demonstrated highest p27 expression in progenitors and higher levels in virgin 
compared to parous mice (Huh et al, manuscript in preparation).  
 Based on our data, we hypothesize, that p27 regulates the proliferation and pool size of 
hormone-responsive luminal progenitors with proliferative potential. Thus, the lower numbers of 
these p27+ cells in control parous women may contribute to their decrease in breast cancer risk. 
High p27 levels and quiescence are maintained in these cells by TGF signaling as implied by 
the co-expression of pSmad2 with p27 and the increase in BrdU incorporation with concomitant 
decrease in p27. Correlating with the presumed importance of TGF signaling and p27 in 
regulating hormone-responsive progenitors, recent whole-genome sequencing studies detected 
CDKN1B and TGF pathway mutations specifically in ER+ breast tumors (Stephens, 2012).  
 In summary, here we describe that the numbers of p27+ cells in the normal breast might be 
used as a biomarker to predict breast cancer risk and to monitor the efficacy of cancer 
preventive strategies. Furthermore, the pathways we identified, especially TGF, might be 
exploited for breast cancer prevention as their modulation could deplete p27+ luminal 
progenitors and consequently decrease breast cancer risk.  
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 EXPERIMENTAL PROCEDURES  
Tissue samples, cell purification, and genomic profiling 
Fresh normal breast tissue specimens were collected at Harvard-affiliated hospitals, at Johns 
Hopkins University School of Medicine, and Baylor-Charles A. Sammons Cancer Center using 
Institutional Review Board-approved protocols. For organ cultures thin (~1mm) slices of 
epithelium-enriched breast tissue were cultured for 8 days in 6-well plates with co-culture inserts 
in M87A medium (Bloushtain-Qimron et al., 2008; Garbe et al., 2009). Detailed protocols for cell 
purification and the generation of SAGE-seq, MSDK-seq, and ChIP-seq libraries are posted on 
our web-site (http://research4.dfci.harvard.edu/polyaklab/protocols_linkpage.php). Genomic 
data were analyzed as described before (Kowalczyk et al., 2011; Maruyama et al., 2011; Wu et 
al., 2010). Semi-quantitative and quantitative RT-PCR and qMSP analyses were performed on 
cells purified from at least 15-20 samples of nulliparous and parous breast tissue as previously 
reported (Bloushtain-Qimron et al., 2008; Hu et al., 2005; Shipitsin et al., 2007). Details of 
genomic data analyses and tissue slice cultures are included in Supplemental Information.  
 
FACS, immunofluorescence, and immunohistochemical analyses 
Single-cell suspension of human breast epithelial cells was obtained essentially as described 
(Bloushtain-Qimron et al., 2008; Shipitsin et al., 2007). Cells were stained with propidium iodine, 
PE/Cy7-CD10 (Biolegend, Clone HI10a), APC-CD24 (Biolegend, clone ML5), and Zenon Alexa 
405 labeled CD44 (BD, Clone 515). Immunohistochemical and immunofluorescence analyses 
were performed essentially as described (Marotta et al., 2011); detailed protocols are included 
in Supplemental Information. 
 
Nurses’ Health Study data 
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The Nurses’ Health Study (NHS) is a prospective cohort study established in 1976. This study 
was approved by the Human Subjects Committee at Brigham and Women’s Hospital in Boston, 
Massachusetts. Breast cancer cases were followed from the date of diagnosis until January 1, 
2008 or death, whichever came first. Ascertainment of deaths included reporting by next of kin 
or postal authorities or searching the National Death Index. Approximately 98% of deaths in the 
NHS have been identified by these methods. Cause of death was ascertained from death 
certificates and physician review of medical records. Information on estrogen receptor (ER) 
status was extracted from the medical record and pathology reports. If data were missing for ER 
status, we used scoring from immunohistochemical staining for ER on 5 µm paraffin sections cut 
from tissue microarray blocks (Tamimi et al., 2008). There were 8,055 women with invasive 
breast cancer diagnosed after return of the 1976 baseline through 2006 questionnaire. One 
woman was excluded due to missing information on parity. Thus, our final analysis included 
8,054 women with invasive breast cancer and information on parity. Survival curves were 
estimated by the Kaplan-Meier method and statistical significance was assessed with the log-
rank test. Multivariate cox proportional hazards regression models were used to evaluate the 
relationship between parity and breast cancer-specific mortality after adjusting for age at 
diagnosis, aspirin use, date of diagnosis, disease stage, grade, radiation treatment, 
chemotherapy and hormonal treatment. All analyses were performed using SAS version 9.1. All 
statistical tests were two sided and P<0.05 was considered statistically significant.  
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FIGURE LEGENDS 
Figure 1. Cell type-specific differences in gene expression according to parity and 
BRCA1/2 mutation status. (A) Genome-wide view of genes differentially expressed between 
nulliparous (N) and parous (P) samples in the four cell types analyzed. Each dot represents a 
gene. Fold differences between averaged N and P samples and their corresponding p-values 
are plotted on the y and x-axis, respectively. Green vertical lines indicate p=0.05, numbers 
indicate genes differentially expressed at p<0.05. (B) Three-dimensional projection of the gene 
expression data onto the first three principal components. Each ball is a different sample; cell 
type and parity are indicated. (C) Hierarchical clustering of CD44+ cells from nulliparous and 
parous control women and parous BRCA1 and BRCA2 mutation carriers. (D) Frequency of 
CD44+, CD24+, and CD10+ cells relative to total human breast epithelial cells. 10 samples each 
from nulliparous and parous groups were analyzed. Each dot represents an individual sample. 
Error bars represent mean ± SEM. (E) Dendrogram depicting hierarchical clustering of signaling 
pathways significantly high in parous or nulliparous samples in any of the four cell types 
analyzed. (F) Heatmap depicting unsupervised clustering of signaling pathways significantly 
down or upregulated in parous compared to nulliparous samples in any of the four cell types 
analyzed. Color scale indicates –log p value of enrichment. Orange rectangles highlight cell 
type-specific or common altered pathways. 
 
Figure 2. Epigenetic differences between nulliparous and parous tissues. (A) Genome-
wide view of differentially methylated genes in CD24+ and CD44+ cells between nulliparous and 
parous samples. All MSDK sites are plotted on the x-axis in the order of p-values of the 
difference between nulliparous and parous samples in CD44+ or CD24+ cells. Log ratios of 
averaged MSDK counts in three N and three P samples are plotted on the y-axis. Green vertical 
lines indicate p=0.01 and the numbers of significant DMRs (p<0.01) are shown. (B) Pathways 
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enriched with genes in CD44+ cells with the indicated difference in DNA methylation between 
nulliparous and parous women. (C) Genes with promoter and gene body DMRs in CD44+ cells 
from nulliparous and parous samples were analyzed for relative enrichment with the indicated 
protein classes and for relative connectivity. X-axes indicate –log10 p-values for enrichment with 
the listed protein classes and the number of overconnected objects, defined as proteins with 
higher than expected numbers of interactions, in each functional category within each group, 
respectively. (D) Pie charts depicting the relative % of genes in different functional categories 
with the indicated gene expression and DNA methylation pattern in CD44+ cells from 
nulliparous and parous women. (E) Scatter plot for MSDK-seq and SAGE-seq data to depict 
correlations between differential promoter methylation and differential gene expression for 
transcription factors. Genes with transcription regulator activity were selected based on Gene 
Ontology (GO0030528) and plotted in a scatter (or starburst) plot for comparison of 
transcriptional and epigenetic differences between parous and nulliparous samples. Each point 
represents a gene with a MSDK-seq site in certain region (promoter: 5kb upstream to 2kb 
downstream from TSS, gene body: 2kb downstream from TSS to the end of gene), and log10(p 
value) is plotted for difference of DNA methylation (x-axis) and expression (y-axis) between 
parous and nulliparous samples. If a MSDK site is hypermethylated or a gene is higher 
expressed in parous, -1 is multiplied to log10 (p value), providing positive values. MSDK-seq 
sites that are significantly (p<0.05) hypo- or hypermethylated in parous or nulliparous samples 
are highlighted in blue. 
 
Figure 3. Expression of p27 in normal breast tissue samples. Representative examples of 
multicolor immunofluorescence analyses of normal mammary epithelium. (A) Expression of p27, 
CD24, and CD44 in breast tissue of premenopausal nulliparous (NP) and parous (P) women. 
Graphs show the quantification of p27 staining intensity in multiple samples. p-value of 
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difference between nulliparous and parous groups are indicated. Immunofluorescence staining 
for p27 and Ki67 in breast tissue from premenopausal (B) and postmenopausal (C) nulliparous 
and parous women. Graph shows frequencies of p27+ and Ki67+ cells in nulliparous (NP) and 
parous (P) samples. p-values of differences between nulliparous and parous groups are 
indicated. (D) Expression of p27 in CD44+ and CD24+ cells and the frequencies of p27+ and 
Ki67+ cells in the breast epithelium of high and low density areas of the same breast from 
parous women. White arrows mark a subpopulation of p27+CD44+ cells. 
 
Figure 4. Hormonal factors and the expression of p27 in normal breast tissues. (A) 
Representative double immunofluorescence staining for p27 and ER in breast tissue from the 
indicated groups of women. Graph shows frequencies of p27+, ER+, and p27+ER+ cells in each 
group of samples. (B) Representative double immunofluorescence staining for p27 and AR in 
breast tissue from premenopausal nulliparous and parous women, and in BRCA1 mutation 
carriers. Graphs show frequencies of p27+ and AR+ cells in each set of samples. (C) 
Representative double immunofluorescence staining for p27 and Ki67 in breast tissue from the 
indicated groups of women. Graphs show frequencies of p27+, Ki67+, and p27+Ki67+ cells in 
each group of samples.  
 
Figure 5. Modulation of p27+ breast epithelial cells and proliferation by hormonal and 
parity-related pathways. (A) Representative hematoxilin and eosin staining depicting 
morphology of breast tissue after 8 days in culture. (B) Representative examples of multicolor 
immunofluorescence analyses of BrdU+, p27+, and Ki67+ cells in control and tissues treated with 
inhibitors of the indicated pathways. (C) Frequency of Ki67+, BrdU+, and p27+ cells in each of 
the indicated conditions. Asterisks indicate significant (p<0.05) differences between control and 
treated groups. (D) Representative images of immunofluorescence analysis of p27 and graph 
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depicting the frequency of p27+ cells in tissue slices treated with hormones mimicking the 
indicated physiologic levels in women.  
 
Figure 6. Signaling pathways regulating p27+ breast epithelial cells. (A) Representative 
examples of multicolor immunofluorescence analyses of pSMAD2, pEGFR, Axin2+, and p27 
cells in control and tissues treated with inhibitors of the indicated pathways. (B) Quantitation of 
differences in the expression of markers reflecting pathway activity between control and 
inhibitor-treated tissues (inhibitor). (C) RGB spectra demonstrating overlap between the 
expression of p27 and the indicated marker. (D) Double immunofluorescence staining for p27 
and pSmad2 in breast tissues from the indicated women. Graph shows frequencies of p27+, 
pSmad2+, and p27+pSmad2+ cells in each group of samples.  
 
Figure 7. Relevance of parity-related gene expression changes to breast cancer. (A) 
Kaplan-Meier plot depicting the probability of breast cancer-specific survival among women with 
invasive ER+ or ER- breast cancer by parity in the Nurses’ Health Study (1976-2006). The P 
value was calculated with use of the log-rank test. (B) Significant association of the presence of 
a parity-related gene signature with overall survival in a cohort of breast cancer patients with 
ER+ tumors. Kaplan-Meier curves and their corresponding log-rank test p-values are shown. 
Overall survival is defined by death from any cause. Top heat map shows the signature from 
down regulated genes after pregnancy and the bottom heat map from up group genes. The 
color bar above heat map indicates the two distinct patients groups separated by the co-
expression of the signature (Green: better survival group. Red: worse survival group). The color 
bar at the right side of heat map indicates effect of pregnancy on genes in breast cancer 
progression. Pink color indicates pregnancy induces gene expression level change in the same 
trend as breast cancer progression. Blue color indicates pregnancy induces gene expression 
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level change in the opposite trend as breast cancer progression. Black bar indicates death.  
 
 
